Effects of propranolol and a number of its analogues on sodium channels
References (17)
- et al.
Brain Res.
(1975) - et al.
Life Sci.
(1979) - et al.
J. biol. Chem.
(1951) - et al.
Experientia
(1979) - et al.
Cardiovas. Res.
(1975) - et al.
Physiol. Rev.
(1974)
Cited by (44)
Clonidine as an adjuvant for propranolol enhances its effect on infiltrative cutaneous analgesia in rats
2016, Neuroscience LettersPropranolol combined with dopamine has a synergistic action in intensifying and prolonging cutaneous analgesia in rats
2015, Pharmacological ReportsCitation Excerpt :Propranolol, the first clinically useful β-adrenergic receptor antagonist, was introduced to the clinical practice in the treatment of cardiovascular diseases [1,2], angina pectoris [3,4], infantile haemangiomas [5,6], many neuropsychiatric disorders [7], dental anxiety [8] and pulmonary hemangioma [9].
Epinephrine as adjuvant for propranolol produces a marked peripheral action in intensifying and prolonging analgesia in response to local dorsal cutaneous noxious pinprick in rats
2014, European Journal of PharmacologyCitation Excerpt :Propranolol as the first clinically useful β-adrenergic receptor antagonist was discovered in 1964 and introduced to the clinical practice in the treatment of cardiovascular diseases (Frullani et al., 1970; Matthews and Baker, 1982).
Propranolol elicits cutaneous analgesia against skin nociceptive stimuli in rats
2012, Neuroscience LettersIntrathecal propranolol displays long-acting spinal anesthesia with a more sensory-selective action over motor blockade in rats
2011, European Journal of PharmacologyCitation Excerpt :It revolutionized the medical management of angina pectoris and is considered to be one of the most important contributions to clinical medicine and pharmacology in the 20th century (Zimmermann et al., 2010). Indications for the use of propranolol are numerous, including the treatment of angina pectoris (Frishman et al., 1989; Zimmermann et al., 2010), hypertension (Frishman et al., 1989), cardiac arrhythmias (Matthews and Baker, 1982), hyperthrophic obstructive cardiomyopathy (Hess et al., 1983), migraine (Linde and Rossnagel, 2004), and in the therapy of many neuropsychiatric disorders (Tchivileva et al., 2010). Recently, propranolol has been introduced as a novel modality for the treatment of proliferating haemangiomas (Buckmiller, 2009; Maturo and Hartnick, 2010; Zimmermann et al., 2010) and dental anxiety (Heaton et al., 2010).
- †
Department of Medicinal Chemistry.